Dr. Tarun Kewalramani, MD

Dr. Kewalramani practices at Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health.

Dr. Kewalramani's NPI, 1538130570, was assigned on January 29, 2006. Dr. Kewalramani graduated from Northwestern University Feinberg Medical School in 1995. Dr. Kewalramani holds Massachusetts license 155424.

Dr. Kewalramani's primary practice is Lahey Clinic, at 41 & 45 Mall Road, Burlington, MA 01803 in Middlesex County. The practice phone is (781) 744-5100.

Dr. Kewalramani's primary practice is Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health. Dr. Kewalramani is also affiliated with Beth Israel Deaconess Medical Center. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Kewalramani to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kewalramani practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Kewalramani's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Kewalramani is licensed in Massachusetts.

CMS data shows 1,080 Medicare services from Dr. Kewalramani across 8 procedure codes in 2024, for 332 Medicare patients. Medicare paid $69,341 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 332 Medicare patients who saw Dr. Kewalramani in 2024. The largest group is 75 to 84, with 144 patients. 72% of them have high blood pressure, and 68% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kewalramani's median patient age at 75, with 47% women.

In 2024, Dr. Kewalramani wrote 544 Medicare Part D claims for 83 patients. 52% of them were for generic drugs. CMS names the drug for 438 of them, across 13 drugs with 11 or more claims each, at $3,807,590 in total drug cost. In 2023, CMS named 499 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Kewalramani for performance year 2024, reported through an alternative payment model (APM). Dr. Kewalramani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kewalramani as offering telehealth.

CMS Open Payments shows 31 general payments to Dr. Kewalramani from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Celgene Corporation paid the most, $6,016.

Dr. Kewalramani graduated from Northwestern University Feinberg Medical School in 1995.